• Home

  • Documents

  • energycommerce.house.gov ·  · 2014-04-23The process followed by FDA in proposing this rule...
6

energycommerce.house.gov ·  · 2014-04-23The process followed by FDA in proposing this rule appears to stand in stark contrast to ... Director of FDA's Center for Drug Evaluation

Embed Size (px)

Citation preview

Page 1: energycommerce.house.gov ·  · 2014-04-23The process followed by FDA in proposing this rule appears to stand in stark contrast to ... Director of FDA's Center for Drug Evaluation
Page 2: energycommerce.house.gov ·  · 2014-04-23The process followed by FDA in proposing this rule appears to stand in stark contrast to ... Director of FDA's Center for Drug Evaluation
Page 3: energycommerce.house.gov ·  · 2014-04-23The process followed by FDA in proposing this rule appears to stand in stark contrast to ... Director of FDA's Center for Drug Evaluation
Page 4: energycommerce.house.gov ·  · 2014-04-23The process followed by FDA in proposing this rule appears to stand in stark contrast to ... Director of FDA's Center for Drug Evaluation
Page 5: energycommerce.house.gov ·  · 2014-04-23The process followed by FDA in proposing this rule appears to stand in stark contrast to ... Director of FDA's Center for Drug Evaluation
Page 6: energycommerce.house.gov ·  · 2014-04-23The process followed by FDA in proposing this rule appears to stand in stark contrast to ... Director of FDA's Center for Drug Evaluation

FDA's Advice on Natural body solution

FDA's Advice on Natural body solution

Education
The fda's approach to enfocement is changing

The fda's approach to enfocement is changing

Business
FDA's Model-Based Strategies in the ICH- E14 Guidelines

FDA's Model-Based Strategies in the ICH- E14 Guidelines

Documents
FDA's warning against la jiao shou shen

FDA's warning against la jiao shou shen

Education
GAO-21-409T, DRUG SAFETY: FDA's Future Inspection Plans

GAO-21-409T, DRUG SAFETY: FDA's Future Inspection Plans

Documents
FDA's Perspectives on Cross- Contamination in CMO ... · 1 FDA's Perspectives on Cross- Contamination in CMO Facilities, Considering High Risk Products Bo Chi, Ph.D. Biotech Manufacturing

FDA's Perspectives on Cross- Contamination in CMO ... · 1 FDA's Perspectives on Cross- Contamination in CMO Facilities, Considering High Risk Products Bo Chi, Ph.D. Biotech Manufacturing

Documents
Regulatory Science in FDA's Center for Devices and Radiological

Regulatory Science in FDA's Center for Devices and Radiological

Documents
FDA's Regulatory Procedures Manual, Chapter 9 - Import

FDA's Regulatory Procedures Manual, Chapter 9 - Import

Documents
Dr. Pat Curtis - FDA's Salmonella Enteritidis Rule for Laying Chickens

Dr. Pat Curtis - FDA's Salmonella Enteritidis Rule for Laying Chickens

Business
Searching for a Cure: The FDA's Regulatory Approach to

Searching for a Cure: The FDA's Regulatory Approach to

Documents
Time for Change: Stepping Up the FDA's Regulation of

Time for Change: Stepping Up the FDA's Regulation of

Documents
FDA's Voluntary Qualified Importer Program Guidance for Industry

FDA's Voluntary Qualified Importer Program Guidance for Industry

Documents
Lifecycle Approach to FDA's Structured Benefit-Risk Assessment

Lifecycle Approach to FDA's Structured Benefit-Risk Assessment

Documents
PEMD-88-30 Medical Devices: FDA's Forecasts of Problem

PEMD-88-30 Medical Devices: FDA's Forecasts of Problem

Documents
FDA's warning against asset bold

FDA's warning against asset bold

Education
Strategies for meeting FDA's UDI Rule

Strategies for meeting FDA's UDI Rule

Government & Nonprofit
Drug Safety Information -- FDA's Communication to the Public (PDF

Drug Safety Information -- FDA's Communication to the Public (PDF

Documents
FDA's Perspectives on Cross- Contamination in CMO ...c.ymcdn.com/sites/casss.site-ym.com/resource/... · FDA's Perspectives on Cross- Contamination in CMO Facilities, Considering

FDA's Perspectives on Cross- Contamination in CMO ...c.ymcdn.com/sites/casss.site-ym.com/resource/... · FDA's Perspectives on Cross- Contamination in CMO Facilities, Considering

Documents
GAO-11-556T Medical Devices: FDA's Premarket Review and

GAO-11-556T Medical Devices: FDA's Premarket Review and

Documents
FDA's warning against B-Perfect

FDA's warning against B-Perfect

Education
PEMD-89-10 Medical Devices: FDA's …regulation, (3) to evaluate FDA'S analysis and use of the MDR data, and (4) to review FDA's efforts to assess the degree to which medical device

PEMD-89-10 Medical Devices: FDA's …regulation, (3) to evaluate FDA'S analysis and use of the MDR data, and (4) to review FDA's efforts to assess the degree to which medical device

Documents
US FDA's Question-based Review for Generic Drugs - ICH

US FDA's Question-based Review for Generic Drugs - ICH

Documents
FDA's 21 CFR 11 rules

FDA's 21 CFR 11 rules

Documents
FDA's advice on asset bee pollen

FDA's advice on asset bee pollen

Education
Cosmetic Labeling: The FDA's Response to Consumer Needs

Cosmetic Labeling: The FDA's Response to Consumer Needs

Documents
Cosmeceuticals or CosmePSEUDOcals: Examining the FDA's Under

Cosmeceuticals or CosmePSEUDOcals: Examining the FDA's Under

Documents
FSMA: Understanding FDA's New Food Safety Rules

FSMA: Understanding FDA's New Food Safety Rules

Documents
Overview of FDA's Regulatory Framework for PET Drugs

Overview of FDA's Regulatory Framework for PET Drugs

Documents
US FDA's PAT Guidance – 10 years and now

US FDA's PAT Guidance – 10 years and now

Education
FDA's Collaborative Efforts to Promote ISO/IEC 17025:2005

FDA's Collaborative Efforts to Promote ISO/IEC 17025:2005

Documents